Whole Genome Sequencing (WGS): The Next Diagnostics Platform

April 3, 2012
11:30 – 1:00 pm EST

Symposium Course Description:
Next generation sequencing technology is transforming the way clinical researchers think about diagnosing inherited genetic disease and classifying leukemias and solid tumors. The question that clinical laboratories are grappling with “is it ready for prime time”? Many clinical laboratories are forging ahead and the market for technology and services in this field is growing rapidly.

Learning Objective:

Why are some clinical labs buying instruments today?
What are the major clinical diagnostics applications?
Which applications are best suited to WGS as opposed to targeted resequencing?
What are the major tailwinds and headwinds to adoption – “test” validation, interpretation, data storage, experts, reimbursement, ethics, regulatory, IP?

Who Should Attend:

Lab Directors
Medical Directors
Informatics Specialists
Lab Executives
NGS Professionals

Instructor Information and Biography:
Katherine Tynan Ph.D, President, Tynan Consulting LLC
Dr. Tynan has over 20 years of experience in clinical diagnostics and technology development. Her team at Tynan Consulting works with investors, early stage and established diagnostics companies and laboratories that are currently developing NGS technologies or services, guiding them through product development choices, market entry strategies, funding and a diverse range of business development transactions. Katherine has previously worked at companies such as Applied Biosystems and was a project lead on the 3700 DNA sequencer. (http://www.linkedin.com/pub/katherine-tynan/0/772/593)